Viking Therapeutics Announces Positive Topline Results From Maintenance Study Of Glp-1/Gip Agonist Vk2735 Demonstrating The Promise Of Multiple Maintenance Dosing Regimens
VKTX•Source note
Source text: ID:nPn7KpWwca
Further company coverage: VKTX.O
Topline maintenance study results
Sept. 22 (Reuters) - Viking Therapeutics, Inc. (VKTX.O):
- Viking Therapeutics announces positive topline results from maintenance study of GLP-1/GIP agonist VK2735 demonstrating the promise of multiple maintenance dosing regimens
- Viking Therapeutics reports 22% placebo-adjusted weight loss at week 33 with VK2735 17.5 mg weekly dosing
- Viking Therapeutics says up to 97% weight loss maintained with every-other-week dosing for three months
- Viking Therapeutics says up to 90% weight loss maintained with monthly dosing for three months
- Viking Therapeutics says maintenance dosing shows GI adverse event rates similar to placebo
